Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
85
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population

N Trachu1 Research Center, Faculty of Medicine Ramathibodi Hospital;2 Molecular Medicine Program, Multidisciplinary Unit, Faculty of Science
,
E Sirachainan3 Division of Medical Oncology, Department of Medicine
,
N Larbcharoensub4 Division of Anatomical Pathology, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University
,
W Rattanadech3 Division of Medical Oncology, Department of Medicine
,
S Detarkom3 Division of Medical Oncology, Department of Medicine
,
N Monnamo1 Research Center, Faculty of Medicine Ramathibodi Hospital
,
K Kamprerasart4 Division of Anatomical Pathology, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University
,
D MunTham5 Section for Mathematic, Faculty of Science and Technology, Rajamangala University of Technology Suvarnabhumi
,
C Sukasem6 Division of Pharmacogenomics and Personalized Medicine, Department of Pathology;7 Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
&
T Reungwetwattana3 Division of Medical Oncology, Department of MedicineCorrespondence[email protected]
 show all
Pages 4955-4968 | Published online: 11 Oct 2017

Figures & data

Figure 1 Kaplan–Meier curve for OS of CCC according to gene alteration.

Notes: (A) OS by EGFR mutation. (B) OS by EGFR T790M mutation and negative EGFR mutation. (C) OS by EGFR T790M mutation and other positive EGFR mutation. (D) OS by PIK3CA mutation. (E) OS by KRAS mutation.
Abbreviations: CCC, cholangiocarcinoma; HR, hazard ratio; mOS, median OS; OS, overall survival.
Figure 1 Kaplan–Meier curve for OS of CCC according to gene alteration.

Figure 2 Kaplan–Meier curve for PFS of CCC according to gene alteration.

Notes: (A) PFS by EGFR mutation. (B) PFS by EGFR T790M mutation and negative EGFR mutation. (C) PFS by EGFR T790M mutation and other positive EGFR mutation. (D) PFS by PIK3CA mutation. (E) PFS by KRAS mutation.
Abbreviations: CCC, cholangiocarcinoma; HR, hazard ratio; mPFS, median PFS; PFS, progressive-free survival.
Figure 2 Kaplan–Meier curve for PFS of CCC according to gene alteration.

Table 1 Molecular alteration in CCC

Table 2 OS and PFS of CCC by molecular analysis (N=81)

Figure 3 Analysis of EGFR T790M mutation using RT-PCR, ddPCR, and Sanger sequencing.

Notes: (A) Amplification curve of sample with EGFR c2369 C>T (T790M) mutation (blue line) and internal control (red line). (B) ddPCR amplitude scatter plot, single-well data for wild-type DNA; mutation assay (FAM, channel 1), wild-type assay (Hex, channel 2). (C) Chromatograms EGFR c2369 C>T (T790M).
Abbreviations: Ch1, channel 1; Ch2, channel 2; ddPCR, droplet digital polymerase chain reaction; FAM, 6-carboxyfluorescein; Hex, hexachloro-6-carboxyfluorescein; neg, negative; pos, positive; RT-PCR, real-time polymerase chain reaction.
Figure 3 Analysis of EGFR T790M mutation using RT-PCR, ddPCR, and Sanger sequencing.

Table 3 Detection of EGFR mutation by qRT-PCR, Sanger sequencing, and ddPCR

Table 4 Demographic and clinical characteristics of patients categorized by mutations

Table 5 Median Ki-67 in each group of molecular analysis and tumor marker

Table S1 List of mutation and cosmic ID identities of EGFR, PIK3CA, KRAS, and BRAF for ARMS-qPCR Amoy Kit

Table S2 List of primers for direct sequencing EGFR (Ref seq: NG_007726.3)

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.